Grey Wolf Therapeutics, a UK-based biotechnology company, announced on Thursday that it has named Brett Carter as a non-executive director to the board of its Australian subsidiary.

Carter has over 20 years of global biopharmaceutical industry experience. He has served as chief executive officer of Australia's Cancer Therapeutics Cooperative Research Centre (now Canthera Discovery). He has served as a strategic advisor to several biotechnology organisations. He has held various roles with GSK in London over an 11-year period, rising to director within its global corporate transactions team.

Carter holds an MBA from London Business School and a BSc from RMIT University, and is a graduate of the Australian Institute of Company Directors.